• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Lamotrigine offers higher net health benefits and is more cost-effective than levetiracetam and zonisamide as first-line focal epilepsy treatment

byAlice WangandTeddy Guo
April 30, 2021
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Lamotrigine offered greater clinical benefit, fewer adverse reactions, and higher cost-utility normalized to quality-adjusted life years compared to levetiracetam and zonisamide.

2. Lamotrigine continues to be recommended as first-line therapy and standard comparator in trials for focal epilepsy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Focal epilepsy causes recurrent seizures limited to one cerebral hemisphere, typically treated with first-line therapies carbamazepine or lamotrigine. Recent studies have suggested non-inferiority of levetiracetam and zonisamide as first-line therapies for treating focal seizures compared to carbamazepine and lamotrigine, but limited long-term effectiveness and cost-utility data have been published. This multicenter, randomized, open-label, controlled, phase 4 trial compares levetiracetam and zonisamide with lamotrigine as first-line treatment options. Patients with a history of unprovoked focal seizures and not currently taking anti-seizure medications were eligible for this study. Participants were randomized equally to the three treatment groups and followed for two years. The primary outcome was time to 12-month remission from seizures, defined as the number of days from randomization to the end of a 12-month seizure-free period. Other outcomes included time to 24-month remission, adverse reactions, inadequate seizure control, and healthy economic evaluation via quality-adjusted life-years (QALYs). According to study results, levetiracetam did not meet non-inferiority criteria when compared to lamotrigine. Though zonisamide did meet non-inferiority criteria, treatment was associated with higher rates of adverse reactions when compared with lamotrigine treatment. Patient reported quality of life and cost utility analysis both favored lamotrigine over levetiracetam and zonisamide. These findings, together, support the continued use of lamotrigine as first-line therapy for focal epilepsy

Click to read the study in The Lancet 

Relevant Reading: The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

RELATED REPORTS

Time-restricted eating does not confer changes in sleep, mood, or quality of life

Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy

2 Minute Medicine Rewind June 30, 2025

In-Depth [randomized controlled trial]: This study recruited 990 patients between May 2013 to June 2017, all of whom were randomly assigned to one of three treatment groups: lamotrigine, levetiracetam, and zonisamide; 959 patients were ultimately included in the final per-protocol analysis. Demographic characteristics and follow-up time were comparable among the three groups. The non-inferiority hazard margin compared to lamotrigine was pre-defined as 1.329. Levetiracetam did not meet non-inferiority with hazard ratio (HR) of 1.18 ([97.5% CI 0.95-1.47] unadjusted, 1.13 [0.91-1.41] adjusted). Zonisamide did meet non-inferiority criteria with HR 1.03 [0.83-1.28] unadjusted, 1.01 [0.81-1.26] adjusted). However, time to 12-month remission in per protocol analyses demonstrated that lamotrigine is superior to both levetiracetam (HR 1.32 [1·05-1.66]) and zonisamide (HR 1.37 [1.08-1.73]). No difference was found for time to 24-month remission. Levetiracetam and zonisamide were both found to have higher rates of adverse reactions (44% and 45%, respectively) compared to lamotrigine (33%), resulting in increased likelihood that patients would fail treatment due to adverse reactions. In terms of cost utility, the net health benefit per QALY was higher with lamotrigine (1.403 [1.319-1.458]) than levetiracetam (1.222 [1.110-1.283]) and zonisamide (1.232 [1.112-1.307]).

This study recruited a small cohort of patients below age 18, limiting the applicability of findings to pediatric populations. There was also heterogeneity in the initial dose patients were prescribed, regardless of randomization as dosing and titration were determined by the treating clinician. The quality of life and cost utility analysis depended critically on patient-reported outcomes, which may be skewed by underreporting or misreporting. Despite these limitations, this study supports lamotrigine as first-line therapy for initial management of focal seizures for both clinical efficacy and cost-effectiveness.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: lamotrigineLevetiracetamneurologyPartial Seizures (Focal Seizures)pediatric neurologySeizureseizureszonisamide
Previous Post

#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma

Next Post

#VisualAbstract: Dolutegravir-containing antiretroviral regimens show effective viral suppression in pregnant women with HIV-1

RelatedReports

Provision of medically-tailored meals linked with lower admissions and medical spending
Chronic Disease

Time-restricted eating does not confer changes in sleep, mood, or quality of life

July 4, 2025
Emergency

Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy

July 1, 2025
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Weekly Rewinds

2 Minute Medicine Rewind June 30, 2025

June 30, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 23, 2025

June 23, 2025
Next Post
#VisualAbstract: Polypill plus aspirin treatment decreases cardiovascular event incidence

#VisualAbstract: Dolutegravir-containing antiretroviral regimens show effective viral suppression in pregnant women with HIV-1

Parental hopes for critically ill children are dynamic

Comparative outcomes between COVID-19 and influenza patients placed on veno-venous extracorporeal membrane oxygenation

#VisualAbstract: Liver metastases and LDH levels may be superior prognostic biomarkers for patients with metastatic melanoma

#VisualAbstract: No differences in survival in patients with esophageal cancer treated with neoadjuvant chemotherapy or chemoradiotherapy followed by esophagectomy

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.